Trial | NCT00895726  Report issue

Title

Pilot Study of APD209 in Cancer Cachexia
Open-Label, Pilot Phase I/II Study of the Efficacy and Safety of APD209 in Patients With Cachexia and Advanced Malignancy

  • Phase

    Phase 2

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    13
Primary Objective:

To assess the efficacy of APD209 in adult patients with active cachexia associated with advanced malignancy and not caused by simple starvation.

Secondary Objective:

To assess the safety of APD209 in patients with advanced malignancy and active cachexia.
Study Started
Mar 31
2009
Primary Completion
Nov 30
2011
Study Completion
Jan 31
2012
Last Update
Jan 13
2012
Estimate

Drug APD209

Oral tablets twice per day for 56 days

APD209 Experimental

Criteria 

Inclusion Criteria:

Involuntary loss of weight of >= 2% in 2 months or >= 5% in 6 months, and ongoing in recent weeks, without (or with successfully treated) secondary causes of impaired oral nutritional intake (simple starvation).
No Results Posted